person · Reporting owner

GOLDSMITH MARK A

Disclosed activity across 2 companies

Tapewire entity: 19850
SEC CIK: 0001246842

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Revolution Medicines, Inc.RVMD · Entity 606	Director · See Remarks	September 16, 2026	September 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Revolution Medicines, Inc.

Report date September 16, 2026 · Filed September 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	267,117	Reported balance After 2026-09-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-09-16 · Sale · Disposed 213 · Balance 267,117 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Common StockSEC Table I · non-derivative	Direct	253,342	Reported balance After 2026-09-16 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2026-09-16 · Sale · Disposed 13,775 · Balance 253,342 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F3: Includes 157,588 restricted stock units.
Common StockSEC Table I · non-derivative	IndirectTrust	594,060	Reported balance Holding disclosure · report date 2026-09-16 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 594,060 F4: Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
Common StockSEC Table I · non-derivative	IndirectTrust	61,424	Reported balance Holding disclosure · report date 2026-09-16 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 61,424 F5: Held by Jonathan Goldsmith Revocable Trust.
Common StockSEC Table I · non-derivative	IndirectTrust	61,424	Reported balance Holding disclosure · report date 2026-09-16 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 61,424 F6: Held by Rebecca Goldsmith Revocable Trust.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3: Includes 157,588 restricted stock units.

F4: Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

F5: Held by Jonathan Goldsmith Revocable Trust.

F6: Held by Rebecca Goldsmith Revocable Trust.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CONSTELLATION PHARMACEUTICALS INC

Report date July 15, 2021 · Filed July 19, 2021

Section 16 reporting ended · disclosed 2021-07-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-07-15 transaction · row 1 1 source row Row 1 · 2021-07-15 · Disposition to issuer · Disposed 89,857 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the "Agreement"), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.57	Direct	Reported balance After 2021-07-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50	Direct	Reported balance After 2021-07-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-07-15 · Disposition to issuer · Disposed 6,825 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.12	Direct	Reported balance After 2021-07-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60	Direct	Reported balance After 2021-07-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-07-15 · Disposition to issuer · Disposed 12,446 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.51	Direct	Reported balance After 2021-07-15 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-07-15 · Disposition to issuer · Disposed 9,083 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.52	Direct	Reported balance After 2021-07-15 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the "Agreement"), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 25, 2025 Filed Nov 26, 2025 21:15 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	3,000	$75.00	$225,000.00	Disclosure SEC source: 0001610717-25-000403 · form4.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 67,424 F5 · ownership.nature: Held by Rebecca Goldsmith Revocable Trust. Read SEC document
November 25, 2025 Filed Nov 26, 2025 21:15 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	3,000	$75.00	$225,000.00	Disclosure SEC source: 0001610717-25-000403 · form4.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 67,424 F4 · ownership.nature: Held by Jonathan Goldsmith Revocable Trust. Read SEC document
November 25, 2025 Filed Nov 26, 2025 21:15 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	60,000	$75.08	$4,504,962.00	Disclosure SEC source: 0001610717-25-000403 · form4.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 247,863 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $75.00 to $75.3650. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 193,475 restricted stock units. Read SEC document
November 25, 2025 Filed Nov 26, 2025 21:15 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	60,000	$4.09	$245,400.00	Disclosure SEC source: 0001610717-25-000403 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F2 · balance_after: Includes 193,475 restricted stock units. Read SEC document
November 18, 2025 Filed Nov 20, 2025 21:23 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-25-000384 · form4.xml · derivative · entry 7 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,708 Underlying: Common Stock · 20,000 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. Read SEC document
November 18, 2025 Filed Nov 20, 2025 21:23 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	20,000	$70.38	$1,407,586.00	Disclosure SEC source: 0001610717-25-000384 · form4.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 247,863 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $70.00 to $70.89. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 193,475 restricted stock units. Read SEC document
November 18, 2025 Filed Nov 20, 2025 21:23 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	20,000	$4.09	$81,800.00	Disclosure SEC source: 0001610717-25-000384 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 267,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F2 · balance_after: Includes 193,475 restricted stock units. Read SEC document
November 12, 2025 Filed Nov 13, 2025 01:12 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GiftCommon Stock	50,000	$0.00	$0.00	Disclosure SEC source: 0001610717-25-000375 · form4.xml · nonDerivative · entry 7 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 54,498 F8 · balance_after: Reflects the transfer of 4,498 shares. F9 · ownership.nature: Held by Rebecca Goldsmith Revocable Trust. Read SEC document
November 12, 2025 Filed Nov 13, 2025 01:12 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GiftCommon Stock	50,000	$0.00	$0.00	Disclosure SEC source: 0001610717-25-000375 · form4.xml · nonDerivative · entry 6 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 70,424 F7 · ownership.nature: Held by Jonathan Goldsmith Revocable Trust. Read SEC document
November 12, 2025 Filed Nov 13, 2025 01:12 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GiftCommon Stock	50,000	$0.00	$0.00	Disclosure SEC source: 0001610717-25-000375 · form4.xml · nonDerivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 247,863 F6 · kind: Represents a transfer to the Rebecca Goldsmith Revocable Trust. F2 · balance_after: Reflects the transfer of 104,446 shares previously held directly by the Reporting Person into a family trust. F3 · balance_after: Includes 193,475 restricted stock units. Read SEC document
November 12, 2025 Filed Nov 13, 2025 01:12 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GiftCommon Stock	50,000	$0.00	$0.00	Disclosure SEC source: 0001610717-25-000375 · form4.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 297,863 F5 · kind: Represents a transfer to the Jonathan Goldsmith Revocable Trust. F2 · balance_after: Reflects the transfer of 104,446 shares previously held directly by the Reporting Person into a family trust. F3 · balance_after: Includes 193,475 restricted stock units. Read SEC document
November 12, 2025 Filed Nov 15, 2025 01:45 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-25-000380 · form4.xml · derivative · entry 7 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,708 Underlying: Common Stock · 20,000 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. Read SEC document
November 12, 2025 Filed Nov 15, 2025 01:45 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	20,000	$65.07	$1,301,410.00	Disclosure SEC source: 0001610717-25-000380 · form4.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 247,863 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $65.00 to $65.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 193,475 restricted stock units. Read SEC document
November 12, 2025 Filed Nov 15, 2025 01:45 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	20,000	$4.09	$81,800.00	Disclosure SEC source: 0001610717-25-000380 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 267,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F2 · balance_after: Includes 193,475 restricted stock units. Read SEC document
November 07, 2025 Filed Nov 13, 2025 01:12 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	3,521	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-25-000375 · form4.xml · derivative · entry 11 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,708 Underlying: Common Stock · 3,521 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. Read SEC document
November 07, 2025 Filed Nov 13, 2025 01:12 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	26,479	$0.00 Strike: $1.12	$0.00	Disclosure SEC source: 0001610717-25-000375 · form4.xml · derivative · entry 10 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,479 shares Expires 2028-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. Read SEC document
November 07, 2025 Filed Nov 13, 2025 01:12 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	30,000	$60.31	$1,809,306.00	Disclosure SEC source: 0001610717-25-000375 · form4.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 347,863 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $60.00 to $60.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Reflects the transfer of 104,446 shares previously held directly by the Reporting Person into a family trust. F3 · balance_after: Includes 193,475 restricted stock units. Read SEC document
November 07, 2025 Filed Nov 13, 2025 01:12 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	3,521	$4.09	$14,400.89	Disclosure SEC source: 0001610717-25-000375 · form4.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 377,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F2 · balance_after: Reflects the transfer of 104,446 shares previously held directly by the Reporting Person into a family trust. F3 · balance_after: Includes 193,475 restricted stock units. Read SEC document
November 07, 2025 Filed Nov 13, 2025 01:12 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	26,479	$1.12	$29,656.48	Disclosure SEC source: 0001610717-25-000375 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 374,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F2 · balance_after: Reflects the transfer of 104,446 shares previously held directly by the Reporting Person into a family trust. F3 · balance_after: Includes 193,475 restricted stock units. Read SEC document
October 17, 2025 Filed Oct 20, 2025 20:18 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $1.12	$0.00	Disclosure SEC source: 0001610717-25-000367 · form4.xml · derivative · entry 9 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,479 Underlying: Common Stock · 10,000 shares Expires 2028-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. Read SEC document
October 17, 2025 Filed Oct 20, 2025 20:18 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	10,000	$55.00	$550,000.00	Disclosure SEC source: 0001610717-25-000367 · form4.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 452,309 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F2 · balance_after: Includes 193,475 restricted stock units. Read SEC document
October 17, 2025 Filed Oct 20, 2025 20:18 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	10,000	$1.12	$11,200.00	Disclosure SEC source: 0001610717-25-000367 · form4.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 462,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F2 · balance_after: Includes 193,475 restricted stock units. Read SEC document
October 16, 2025 Filed Oct 20, 2025 20:18 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $1.12	$0.00	Disclosure SEC source: 0001610717-25-000367 · form4.xml · derivative · entry 8 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,479 Underlying: Common Stock · 10,000 shares Expires 2028-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. Read SEC document
October 16, 2025 Filed Oct 20, 2025 20:18 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	10,000	$50.47	$504,701.00	Disclosure SEC source: 0001610717-25-000367 · form4.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 452,309 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.93. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 193,475 restricted stock units. Read SEC document
October 16, 2025 Filed Oct 20, 2025 20:18 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	10,000	$1.12	$11,200.00	Disclosure SEC source: 0001610717-25-000367 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 462,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. F2 · balance_after: Includes 193,475 restricted stock units. Read SEC document
September 16, 2025 Filed Sep 18, 2025 20:37 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	13,411	$45.82	$614,557.73	Disclosure SEC source: 0001610717-25-000349 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 452,309 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 193,475 restricted stock units. Read SEC document
June 30, 2025 Filed Jul 2, 2025 20:11 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	37,000	$0.00 Strike: $0.54	$0.00	Disclosure SEC source: 0001610717-25-000274 · form4.xml · derivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,503 Underlying: Common Stock · 37,000 shares Expires 2028-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 30, 2025 Filed Jul 2, 2025 20:11 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	37,000	$0.54	$19,980.00	Disclosure SEC source: 0001610717-25-000274 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 465,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 218,188 restricted stock units. Read SEC document
June 16, 2025 Filed Jun 18, 2025 20:06 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	13,496	$39.83	$537,545.68	Disclosure SEC source: 0001610717-25-000241 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 428,720 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $39.6016 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025. F4 · balance_after: Includes 218,188 RSUs. Read SEC document
March 17, 2025 Filed Mar 19, 2025 21:43 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	11,738	$39.04	$458,255.04	Disclosure SEC source: 0001610717-25-000080 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 441,564 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 242,900 RSUs. Read SEC document
March 01, 2025 Filed Mar 5, 2025 00:00 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantStock Option (Right to Buy) · Derivative	341,100	$0.00 Strike: $40.74	$0.00	Disclosure SEC source: 0001610717-25-000050 · form4.xml · derivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 341,100 shares Expires 2035-02-28 F5 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document
March 01, 2025 Filed Mar 5, 2025 00:00 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantCommon Stock	97,400	$0.00	$0.00	Disclosure SEC source: 0001610717-25-000050 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 453,302 F1 · balance_after: Includes 264,525 restricted stock units. Read SEC document
December 18, 2024 Filed Dec 20, 2024 21:50 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	30,846	$0.00 Strike: $0.49	$0.00	Disclosure SEC source: 0001610717-24-000548 · form4.xml · derivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,846 shares Expires 2027-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 18, 2024 Filed Dec 20, 2024 21:50 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	30,846	$0.49	$15,114.54	Disclosure SEC source: 0001610717-24-000548 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 355,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 167,125 restricted stock units. Read SEC document
December 16, 2024 Filed Dec 18, 2024 21:08 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	11,714	$45.40	$531,860.11	Disclosure SEC source: 0001610717-24-000546 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 325,056 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 167,125 RSUs. Read SEC document
November 04, 2024 Filed Nov 5, 2024 21:21 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	36,600	$0.00 Strike: $0.49	$0.00	Disclosure SEC source: 0001610717-24-000517 · form4.xml · derivative · entry 11 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,846 Underlying: Common Stock · 36,600 shares Expires 2027-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. Read SEC document
November 04, 2024 Filed Nov 5, 2024 21:21 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	50,900	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-24-000517 · form4.xml · derivative · entry 10 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,229 Underlying: Common Stock · 50,900 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. Read SEC document
November 04, 2024 Filed Nov 5, 2024 21:21 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	36,600	$0.49	$17,934.00	Disclosure SEC source: 0001610717-24-000517 · form4.xml · nonDerivative · entry 8 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 336,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F2 · balance_after: Includes 188,750 restricted stock units. Read SEC document
November 04, 2024 Filed Nov 5, 2024 21:21 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	50,900	$55.56	$2,827,820.76	Disclosure SEC source: 0001610717-24-000517 · form4.xml · nonDerivative · entry 7 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 300,170 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F8 · price: This transaction was executed in multiple trades in prices ranging from $55.00 to $55.87, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 188,750 restricted stock units. Read SEC document
November 04, 2024 Filed Nov 5, 2024 21:21 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	50,900	$4.09	$208,181.00	Disclosure SEC source: 0001610717-24-000517 · form4.xml · nonDerivative · entry 6 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 351,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F2 · balance_after: Includes 188,750 restricted stock units. Read SEC document
November 01, 2024 Filed Nov 5, 2024 21:21 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	9,100	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-24-000517 · form4.xml · derivative · entry 9 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 232,129 Underlying: Common Stock · 9,100 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. Read SEC document
November 01, 2024 Filed Nov 5, 2024 21:21 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	5,000	$55.02	$275,104.50	Disclosure SEC source: 0001610717-24-000517 · form4.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 20,424 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F4 · price: This transaction was executed in multiple trades in prices ranging from $55.00 to $55.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F6 · ownership.nature: Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011. Read SEC document
November 01, 2024 Filed Nov 5, 2024 21:21 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	5,000	$55.03	$275,134.00	Disclosure SEC source: 0001610717-24-000517 · form4.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 20,424 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F4 · price: This transaction was executed in multiple trades in prices ranging from $55.00 to $55.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F5 · ownership.nature: Held by Jonathan Goldsmith Revocable Trust. Read SEC document
November 01, 2024 Filed Nov 5, 2024 21:21 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	9,100	$55.02	$500,713.85	Disclosure SEC source: 0001610717-24-000517 · form4.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 300,170 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F3 · price: This transaction was executed in multiple trades in prices ranging from $55.00 to $55.17, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 188,750 restricted stock units. Read SEC document
November 01, 2024 Filed Nov 5, 2024 21:21 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	9,100	$4.09	$37,219.00	Disclosure SEC source: 0001610717-24-000517 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F2 · balance_after: Includes 188,750 restricted stock units. Read SEC document
October 11, 2024 Filed Oct 15, 2024 21:30 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-24-000508 · form4.xml · derivative · entry 6 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 241,229 Underlying: Common Stock · 30,000 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. Read SEC document
October 11, 2024 Filed Oct 15, 2024 21:30 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	30,000	$50.36	$1,510,773.00	Disclosure SEC source: 0001610717-24-000508 · form4.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 300,170 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F3 · price: This transaction was executed in multiple trades in prices ranging from $50.00 to $50.82, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 188,750 restricted stock units. Read SEC document
October 11, 2024 Filed Oct 15, 2024 21:30 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	30,000	$4.09	$122,700.00	Disclosure SEC source: 0001610717-24-000508 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 330,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F2 · balance_after: Includes 188,750 restricted stock units. Read SEC document
October 01, 2024 Filed Oct 3, 2024 20:33 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-24-000501 · form4.xml · derivative · entry 7 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 271,229 Underlying: Common Stock · 10,000 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. Read SEC document
October 01, 2024 Filed Oct 3, 2024 20:33 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	2,022	$45.46	$91,913.25	Disclosure SEC source: 0001610717-24-000501 · form4.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 300,170 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F4 · price: This transaction was executed in multiple trades in prices ranging from $45.32 to $45.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 188,750 restricted stock units. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.